SecBot SecBot

RCUS drug pipeline

Arcus Biosciences, Inc. · 5 rated drugs
$16.86
−3.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
5
1 bearish · 1 mixed · 3 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-6 years minimum. Quemliclustat is in Phase 2 testing with primary completion estimated January 2027. If successful, it would need to advance to Phase 3 and then regulatory filing, putting potential approval/commercialization at least several years away.

quemliclustat Updated Oct 24

What to watch

The next hard catalyst for quemliclustat is the Phase 2 primary completion readout from trial NCT05329766, estimated for January 2027. However, this is a secondary pipeline asset at Arcus, the stock's primary value driver is casdatifan (HIF-2α inhibitor). Watch for topline data from the GI malignancy trial in early 2027, but expect the stock to move more on casdatifan and domvanalimab catalysts than on quemliclustat alone.

Bull case
  • Quemliclustat is being tested in a rational combination with domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) plus chemotherapy, a multi-pronged immunotherapy approach targeting multiple immune checkpoints and the adenosine pathway simultaneously.
  • The Phase 2 trial (NCT05329766) is fully enrolled (332 patients) and active but not recruiting, meaning data collection is underway with estimated primary completion in January 2027.
  • Arcus has strong analyst support, 16 Buy/Strong Buy ratings vs 0 Sell, with a mean price target of $41 (121% upside from $18.54), suggesting the market sees value in the broader pipeline including quemliclustat.
Bear case
  • Quemliclustat is a secondary pipeline asset at Arcus, the company's primary focus and capital allocation is on casdatifan (HIF-2α inhibitor), which received the bulk of the $250M October 2026 offering proceeds. Quemliclustat may be deprioritized if casdatifan requires more resources.
  • The Phase 2 trial (NCT05329766) has no posted results yet and the estimated primary completion is January 2027, nearly 5 years after trial start in June 2022, suggesting enrollment or data collection challenges.
  • CD73 inhibitors as a class have faced mixed clinical results across the industry, with several programs failing to show clear benefit over standard-of-care checkpoint inhibitors.
◆ mixed
Impact
PhasePhase 2
Time to marketEstimated 3-5 years. The drug is in Phase 2; a Phase 3 registrational trial has not yet been initiated. Even with a potential accelerated path, FDA submission is likely several years away.

casdatifan Updated Oct 23

What to watch

Watch for the next ARC-20 data update at a medical conference (likely 2027) and any announcement of a Phase 3 registrational trial start. The $250M capital raise at a discount signals near-term cash needs despite positive data; monitor for further dilution risk. The stock is technically oversold (RSI 27.5) with strong analyst support, but no hard binary catalyst is scheduled within the next 12 months.

Bull case
  • Phase 2 ARC-20 data showed compelling efficacy: 50% cORR in first-line combination and 36% cORR in late-line monotherapy in ccRCC, a large addressable market
  • Analyst consensus is Strong Buy (16 analysts: 11 Buy, 5 Strong Buy, 3 Hold) with a mean price target of $41, 134.6% upside from the current $18.54
  • Multiple institutional investors added or doubled positions in Q2 2026, including Citadel, FMR, JPMorgan, and Goldman Sachs
Bear case
  • Merck's Welireg (belzutifan) is already FDA-approved as a HIF-2α inhibitor for VHL-associated RCC and is being studied in broader ccRCC, casdatifan faces a first-mover disadvantage
  • The $250M public offering at $17.50/share (8.4% discount) caused 11.2% dilution and signals urgent cash needs despite a ~$694M cash balance
  • Cash burn is accelerating at ~$182M/quarter, up from ~$134M in Q1 2026, suggesting the company may need additional capital within 12-18 months
● neutral
Impact
PhasePhase 3
Time to marketUnknown. Zimberelimab is investigational in the US with no FDA submission or PDUFA date identified. The drug is furthest along in combination with domvanalimab, but no regulatory filing has been announced. If pivotal data from the completed Phase 3 STAR-221 trial supports a filing, a BLA submission could come in 2027 at the earliest, with potential approval in 2028-2029.

zimberelimab Updated Oct 23

What to watch

Zimberelimab is not a standalone binary catalyst, watch for domvanalimab+zimberelimab combination data readouts from the completed Phase 3 STAR-221 (NCT05568095) and the ongoing EDGE-Gastric study. RCUS recently completed a dilutive $250M offering at $17.50/share; monitor Q3 2026 earnings (Oct 26 or Nov 10) for cash runway updates and pipeline progress.

Bull case
  • Zimberelimab is a fully human anti-PD-1 antibody with a clean safety profile and demonstrated efficacy across multiple tumor types, as published in peer-reviewed journals (Frontiers in Oncology, Nature Medicine, Nature Communications)
  • The drug serves as the backbone of Arcus' combination immunotherapy pipeline with domvanalimab (anti-TIGIT), which has shown promising efficacy signals in NSCLC and GI cancers, a differentiated approach vs. Keytruda monotherapy
  • Arcus has a deep-pocketed partner in Gilead Sciences (2020 collaboration worth up to $1.9B), providing financial support and development infrastructure
Bear case
  • Zimberelimab is entering a crowded PD-1 inhibitor market dominated by established blockbusters Keytruda (pembrolizumab, Merck) and Opdivo (nivolumab, BMS), differentiation will be difficult without clear superiority
  • No FDA approval or regulatory filing has been announced for zimberelimab in any indication; the drug remains investigational with an uncertain path to market
  • Arcus recently completed a dilutive $250M stock offering at $17.50/share (8.4% discount), with ~$182M quarterly cash burn, the company may need additional capital within 12 months
▼ bearish
Impact
PhasePhase 3 (discontinued)
Time to marketUnknown — program largely discontinued; no path to market

domvanalimab Updated Oct 24

What to watch

Domvanalimab is effectively a failed program after two Phase 3 discontinuations for futility. Arcus has pivoted to its HIF2 inhibitor casdatifan (casdatifan) as the lead pipeline asset. Investors should watch for the Q3 2026 earnings (Oct 26 or Nov 11) for cash runway updates and casdatifan Phase 3 PEAK-1 enrollment data, those are now the real value drivers for RCUS, not domvanalimab.

Bull case
  • Domvanalimab showed some encouraging Phase 2 data in combination with zimberelimab in PD-L1-high NSCLC (ARC-7 study) and in immunotherapy-refractory HCC and BTC (Nature Communications publications).
  • The Fc-silent design is mechanistically differentiated from Roche's tiragolumab and may still have potential in certain niches or earlier lines.
  • Analyst consensus on RCUS remains strong: 16 Buy/Strong Buy vs 3 Hold, mean price target $41 (134.6% upside from $18.54), suggesting the Street sees value in the rest of the pipeline.
Bear case
  • Domvanalimab failed two Phase 3 trials (STAR-221 in gastric/esophageal cancer and STAR-121 in NSCLC), both discontinued due to futility, representing a total loss of the TIGIT program's value (Gilead press release Dec 2025; Taiho press release Apr 2026).
  • Gilead has loosened its collaboration ties with Arcus after the TIGIT failures, ending broader option rights in July 2026, reducing partnership revenue potential (FierceBiotech reporting).
  • The entire TIGIT class has struggled in the clinic, Roche's tiragolumab also failed multiple Phase 3 trials, raising questions about the mechanism itself.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

AB102 Updated Oct 24

What to watch

AB102 is not identifiable in any public database or filing associated with Arcus Biosciences. Investors should not base any trading decisions on this drug name until the company formally discloses it in a pipeline update, SEC filing, or press release. Monitor Arcus' upcoming Q3 2026 earnings call (expected late October/early November 2026) for any pipeline updates.

Bull case
  • No bullish thesis can be constructed, AB102 is not identifiable in any public source associated with Arcus Biosciences.
Bear case
  • AB102 may not exist as a real development candidate; it could be a typo or an internal code that was never disclosed.
  • If AB102 could be a very early-stage asset that has not been publicly disclosed, it carries all the standard preclinical risk with no data to evaluate.
  • Arcus Biosciences has a ~$182M quarterly cash burn rate of ~$182M/quarter (per the Oct 2026 filing) and recently completed a $250M dilutive offering at $17.50/share, so any new program would require additional capital.

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
domvanalimabStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerPhase 2Completed169Sep 17, 2026
domvanalimabA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesPhase 2Completed332Sep 7, 2026
domvanalimabA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyPhase 3Completed1,040Aug 28, 2026
domvanalimabStudy to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerPhase 2Completed151Jul 9, 2025